Cesca Therapeutics Inc. (KOOL)

0.47
NASDAQ : Health Technology
Prev Close 0.49
Day Low/High 0.47 / 0.49
52 Wk Low/High 0.46 / 6.44
Avg Volume 331.90K
Exchange NASDAQ
Shares Outstanding 11.48M
Market Cap 5.64M
EPS -3.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Cesca Therapeutics Expands CAR-TXpress™ Intellectual Property Portfolio With Filing Of New Patent Covering Cell Activation & Transduction

Cesca Therapeutics Expands CAR-TXpress™ Intellectual Property Portfolio With Filing Of New Patent Covering Cell Activation & Transduction

Invention further streamlines ThermoGenesis' CAR-TXpress workflow, improving efficiency and reducing costs

Cesca Therapeutics Announces Issuance Of Second Cellular Processing Patent

Cesca Therapeutics Announces Issuance Of Second Cellular Processing Patent

Intellectual Property Position Surrounding the Company's X-BACS Technology is Significantly Strengthened

Cesca Therapeutics Announces Financial Results For The Three Months Ended September 30, 2017 And Provides Corporate Update

Cesca Therapeutics Announces Financial Results For The Three Months Ended September 30, 2017 And Provides Corporate Update

Conference Call to be Held at 4:30 p.m. EST (1:30 p.m. PST)

Cesca Therapeutics Announces Fiscal Year 2017 Financial And Operating Results And Provides Corporate Update

Cesca Therapeutics Announces Fiscal Year 2017 Financial And Operating Results And Provides Corporate Update

Conference Call to be Held at 4:30 p.m. EDT (1:30 p.m. PDT)

Biotech Movers: Cesca Up Strong After Securing CAR-T Cell Patent

Biotech Movers: Cesca Up Strong After Securing CAR-T Cell Patent

And a management shakeup helps push down NuVasive.

Cesca Therapeutics Announces Issuance Of New Cellular Processing Patent Poised To Revolutionize CAR-T Cell Manufacturing

Cesca Therapeutics Announces Issuance Of New Cellular Processing Patent Poised To Revolutionize CAR-T Cell Manufacturing

Next-generation automated technology isolates and harvests rare cell types with superior purity, recovery, and viability, and is well suited to the high production demands of immunotherapy drugs

Cesca Therapeutics Acquires The Cell Processing Systems Of SynGen Under Asset Acquisition Agreement

Cesca Therapeutics Acquires The Cell Processing Systems Of SynGen Under Asset Acquisition Agreement

Combined product portfolio strengthens Cesca's position as a leading developer of systems for automated manufacturing of cell-based therapeutics in immuno-oncology and other indications

TheStreet Quant Rating: D- (Sell)